Drug Profile
Research programme: cancer therapeutics - Abraxis BioScience
Alternative Names: ABI-010; ABI-013; ABI-139; nab®-17AAG; nab®-ABI-139; nab®-CY196; NTB-010Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Abraxis BioScience
- Developer Celgene Corporation
- Class Albumins; Antisense oligonucleotides; Taxanes
- Mechanism of Action Antisense RNA inhibitors; HSP90 heat-shock protein inhibitors; Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours